NeuroOne Expands Emily Johns' Role to Chief Administrative Officer Amid Growth Phase

NeuroOne Medical Technologies Corporation has elevated Emily Johns to the expanded position of Chief Administrative Officer while she continues serving as General Counsel, a move that underscores the company's commitment to strengthening its operational foundation during a period of accelerated growth. Johns, who joined NeuroOne earlier this year as General Counsel, will now oversee human resources, compliance, security, and risk management in addition to leading the company's legal strategy.

Dave Rosa, President and CEO of NeuroOne, emphasized the significance of this promotion, stating that Johns has already made impactful contributions to the organization and the future growth of the business since joining the company. The expanded role comes as NeuroOne continues scaling its operations to bring its medical technologies to more patients suffering from neurological disorders.

Johns brings substantial experience to her new position, having most recently served as a partner at Honigman LLP, where she represented numerous life sciences companies, including NeuroOne on all transactional work since 2017. Her background includes beginning her career at Sullivan & Cromwell LLP, where she represented public companies in securities offerings and merger and acquisition transactions. She holds a J.D. from UCLA School of Law and a bachelor's degree from the University of Michigan.

The promotion signals NeuroOne's strategic focus on building robust operational infrastructure as the company advances its portfolio of minimally invasive solutions for neurological conditions. NeuroOne is developing and commercializing hi-definition solutions for EEG recording, stimulation, and ablation for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. The company's technologies aim to improve patient outcomes while reducing procedural costs.

This leadership expansion occurs as NeuroOne explores additional applications for its technology in areas such as depression, mood disorders, pain management, incontinence, high blood pressure, and artificial intelligence. The company's continued growth and development efforts can be tracked through its corporate website at https://www.nmtc1.com and regulatory filings with the Securities and Exchange Commission.

For investors and industry observers, this executive promotion represents NeuroOne's commitment to strengthening its corporate governance and operational capabilities during a critical growth phase. The company's focus on building experienced leadership teams positions it to navigate the complex regulatory landscape of medical technology while scaling its innovative solutions for neurological care.